In this episode, Roger Bedimo, MD, MS, FACP, discusses key considerations to PrEP barriers in adolescents, including: New HIV diagnoses in the United StatesAdherence barriersHealthcare professional barriersConsent laws for minors to receive sexually transmitted infection diagnosis and treatment services Interventions to support PrEP adherence Presenter: Roger Bedimo, MD, MS, FACPProfessor of MedicineDivision of Infectious DiseasesUniversity of Texas UT Southwestern Medical CenterSection ChiefDepartment of Internal MedicineVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ZpM6uuFollow along with the slides:https://bit.ly/3LyGgBj

In this episode, Brooke Bates, PharmD, BCPS, AAHIVP, and Neha Sheth Pandit, PharmD, AAHIVP, BCPS, discuss the most clinically relevant studies on HIV adverse events presented at IAS 2023, including: REPRIEVE study of pitavastatin for cardiovascular prevention in people living with HIV at low to moderate cardiovascular riskData on weight change with switch from integrase inhibitor–based ART to doravirine/islatravir in the P017 and P018 studiesDEFINE study evaluating weight change after a switch to DRV/COBI/FTC/TAF in people living with HIV who experienced weight gain with integrase inhibitor–based ARTFaculty: Brooke Bates, PharmD, BCPS, AAHIVPSpecialty Pharmacy Clinical Manager Pediatric HIV Clinical PharmacistIndiana University HealthIndianapolis, IndianaNeha Sheth Pandit, PharmD, AAHIVP, BCPSProfessorVice Chair for Research and ScholarshipDepartment of Practice, Sciences, and Health Outcomes ResearchSchool of PharmacyUniversity of Maryland Clinical PharmacistTHRIVE ProgramBaltimore, MarylandLink to full program: https://bit.ly/3ZjSFhg

In this episode, Tony Brown, MPH, discusses the importance of effective patient‒provider communication in supporting PrEP persistence including: His own experience with PrEP and reasons for fluctuations in adherence over the years The importance of open, honest, and judgement-free conversations about sexual health Engaging patients in conversations about PrEP effectiveness, adverse effects, and changing life circumstances Working together to find the most effective PrEP option for each individual patient that will help them to persist on PrEP long term Faculty: Tony Brown, MPH PrEP User and Advocate Doctoral Candidate Health Services Policy and Management University of South Carolina Columbia, South Carolina Link to full program: https://bit.ly/3ZlICsL

In this episode, Jill Blumenthal, MD, MAS, and Kenric B. Ware, PharmD, MBA, AAHIVP, answer questions about HIV PrEP including:Considerations for selecting between oral and injectable PrEP in college studentsStrategies to promote PrEP persistence in adolescents Best approaches to address readiness to start PrEP in adolescents (eg, creating nonjudgmental environments, addressing misconceptions)Considerations for local consent lawsAvailable data on PrEP young adolescents (eg, age and weight limits)Initiatives in place to address racial and ethnic disparities associated with PrEP uptake and persistence The role of on-demand PrEP in transgender individuals receiving gender-affirming hormone therapy Offering patient-centered care Educating healthcare professionals on how to prescribe PrEPFaculty: Jill Blumenthal, MD, MAS Associate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaKenric B. Ware, PharmD, MBA, AAHIVP Clinical Associate ProfessorDepartment of Pharmacy PracticeMercer University College of PharmacyAtlanta, GeorgiaLink to full program: https://bit.ly/3Fqdgs9

In this episode, Nikos Dedes, Jeff Taylor, and Bernadette Sharp—people living with HIV—discuss how switching to long-acting ART has affected their quality of life. They are joined by 2 healthcare professionals—Iskandar Azwa,MBChB, MRCP, and Beng Eu, MBBS—who provide insights on how they assess and document health-related quality of life for their patients. The discussion focuses on personal experiences with how LA ART has improved health-related quality of life, including:Avoidance of drug–drug interactionsImproved confidentiality Decreased stigmaPresenters:Iskandar Azwa, MBChB, MRCPAssociate ProfessorInfectious DiseasesFaculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaNikos DedesPositive VoiceAthens, GreeceBeng Eu, MBBSDoctorPrahran Market Clinic Melbourne, Victoria, AustraliaBernadette SharpAdvocateJeff TaylorExecutive DirectorHIV+Aging Research ProjectPalm Springs, CaliforniaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.Link to downloadable slides: https://bit.ly/488WwT7Link to full program: bit.ly/3EwEnRJ

In this episode, Iskandar Azwa, MBChB, MRCP; Nikos Dedes; Beng Eu, MBBS; Bernadette Sharp; and Jeff Taylor discuss challenges and opportunities with long-acting ART implementation, including:Personal experiences with receiving LA ART Views on long-acting ART in the development pipelinePerspectives on self-administration of LA ARTPresenters:Iskandar Azwa, MBChB, MRCPAssociate ProfessorInfectious DiseasesFaculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaNikos DedesPositive VoiceAthens, GreeceBeng Eu, MBBSDoctorPrahran Market Clinic  Melbourne, Victoria, AustraliaBernadette SharpAdvocateJeff TaylorExecutive DirectorHIV+Aging Research ProjectPalm Springs, CaliforniaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.Link to downloadable slides: https://clinicaloptions.com/CE-CME/infectious-disease/slides-fourth-90-and-la-art/17553-25368  Link to full program: https://bit.ly/3EwEnRJ

In this episode, Raphael J. Landovitz, MD, MSc, and Hyman Scott, MD, MPH, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: Misconceptions about PrEP eligibility Strategies to improve lab monitoring on PrEP Leveraging patient navigators and clinic staff to expand PrEP accessData on PrEP efficacy in key populations (eg, transgender men, people who inject drugs)Considerations for prescribing on-demand and same-day PrEP Addressing healthcare professional hesitancy to prescribe PrEPUS Preventive Services Task Force PrEP guideline updatesBundling sexually transmitted infection services with PrEPFacultyRaphael J. Landovitz, MD, MScProfessor of MedicineDivision of Infectious DiseasesDavid Geffen School of MedicineUniversity of California, Los AngelesDirector, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment Services Los Angeles, CaliforniaHyman Scott, MDAssistant Clinical ProfessorDepartment of MedicineUniversity of California, San FranciscoClinical Research Medical DirectorBridge HIVSan Francisco Department of Public HealthSan Francisco, CaliforniaLink to full program: https://bit.ly/3PZGYdR

In this episode, Angela Branche, MD, discusses the Advisory Committee on Immunization Practices recommendations for RSV vaccines in older adults, including: Use of shared clinical decision-making How to approach the conversation about the RSV vaccine with patientsKey populations who may benefit the most, such as those at risk for severe RSV disease (eg, increasing age and persons who are frail or have cardiopulmonary comorbidities)Faculty: Angela Branche, MDAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkLink to full program: https://bit.ly/3nb25xeLink to downloadable slides: https://bit.ly/3nb25xe

In this episode, Renslow Sherer, MD, discusses managing virologic failure in a person living with HIV who is heavily treatment experienced, including:Guideline recommendations for selecting a new ART regimenOptions for patients with multidrug-resistant HIV from existing drug classes and novel mechanisms of action with no cross-resistanceData from TMB-301 and TMB-311 for ibalizumab, BRIGHTE for fostemsavir, and CAPELLA for lenacapavir on the use of these agents for people living with HIV who are heavily treatment experienced with multidrug-resistant HIVPresenter:Renslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTo download the slides:https://bit.ly/3OcqxIETo view the full online program:https://bit.ly/3ZjSFhg

In this episode, Oni Blackstock, MD, MHS, and Brittany Williams, PhD,discuss key considerations to pre-exposure prophylaxis (PrEP) uptake in cisgender women, including: The misconception by patients and healthcare professionals (HCP) that cisgender women are at low risk for HIV Reframing HIV prevention from “risks” to “reasons” such as promoting self-care and taking control of one’s own sexual healthCDC PrEP guidance recommendations Increasing PrEP awareness by sharing PrEP experiences with others in the communityThe importance of community representation in PrEP marketing and campaigns Challenges with finding HCPs who prescribe PrEP for cisgender womenPromoting self-advocacy when seeking care, including HIV prevention Strategies for patients to engage with their HCPs to learn about and obtain PrEP Available resources for PrEP coverage Faculty:  Oni Blackstock, MD, MHSFounder & Executive DirectorHealth JusticeNew York, New York Brittany Williams, PhDAssistant Professor of Higher Education and Student Affairs AdministrationDepartment of EducationUniversity of VermontBurlington, Vermont Link to full program: https://bit.ly/3PZGYdR

In this episode, Kyle Molina, PharmD, BCIDP, discusses key considerations for successful implementation of long-acting lipoglycopeptides into clinical practice. Listen as he gives perspectives on:Reasons to consider use of long-acting lipoglycopeptides (eg, poor adherence to oral antibiotics, PICC-related costs and complications)Data supporting and challenging cost effectiveness of long-acting lipoglycopeptides Identifying the target patient populationSelecting the right location to provide long-acting lipoglycopeptides Strategies to maximize institutional impact with key stakeholders (eg, hospital avoidance, reduced ED and hospital length of stay) Key characteristics of available long-acting lipoglycopeptides Addressing logistical challenges, including navigating the reimbursement process Faculty:Kyle Molina, PharmD, BCIDPInfectious Diseases Clinical PharmacistScripps Green HospitalLa Jolla, CaliforniaLink to full program: CCO: https://bit.ly/3J4mg8hProCE: https://bit.ly/3P0vB4E

In this episode, Joseph Ahn, MD, MS, MBA; Christina Delacruz Leyson, MD; and Alice Chan, a person who experienced pregnancy as a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in people of childbearing potential and their infants, including:HBV screening and vaccination in pregnancyManagement of pregnant people who are HBsAg positiveInfant careBreastfeedingPresenters: Joseph Ahn, MD, MS, MBAProfessor of Medicine, Section ChiefDivision of Gastroenterology and HepatologyOregon Health & Science UniversityPortland, OregonChristina Delacruz Leyson, MDAssociate ProfessorMedical Director, Liver Transplant ProgramProgram Director, Hepatology FellowshipUniversity of KentuckyLexington, KentuckyAlice Chan, person living with chronic hepatitis BLink to downloadable slides:https://bit.ly/3rXLTC7Link to program: https://bit.ly/3L3Kz6l

In this episode, Daniel R. Kuritzkes, MD, and Cristina Mussini, MD, discuss managing ART failure, including:The definitions of virologic blips, low-level viremia, and virologic failure on ARTThe infrequency of failure with resistance on first-line INSTI-based ART and the instances where this has occurred with BIC- and DTG-based ART in clinical trials and in the real worldThe potential reasons for ART failure, including patient/adherence-related factors, HIV-related factors, and regimen-related factorsThe impact of adherence on viral suppression with BIC- and DTG-based ARTDrug-drug interactions as a reason for failure of first-line INSTI-based ARTWhat to do if someone is experiencing virologic failure requiring an ART changeThe use of proviral DNA testing in patients with viral suppression or low-level viremia with ART treatment experienceThe impact of high HIV-1 RNA on ART effectivenessThe impact of NRTI resistance, including the M184V and K65R mutations, on the effectiveness of BIC- and DTG-based ARTStrategies to encourage and measure patient adherence to ART PresentersDaniel R. Kuritzkes, MDHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolChief, Division of Infectious DiseasesBrigham and Women’s HospitalBoston, MassachusettsCristina Mussini, MDProfessorDepartment of Infectious DiseasesUniversity of Modena and Reggio EmiliaModena, ItalyLink to full program: https://bit.ly/3HPu4Lk

In this episode, Renslow Sherer, MD, discusses managing a first ART failure in the setting of COVID-19, including:Guideline recommendations for resistance testingGuideline recommendations for selecting a new ART regimenData on retained efficacy of NRTIs in second-line regimens in the EARNEST and NADIA studiesConsideration of drug‒drug interactions between ART and COVID-19 treatmentPresenter: Renslow Sherer, MDDirector International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois To download the slides: https://bit.ly/3OcqxIE To view the full online program: https://bit.ly/3ZjSFhg

In this episode, Kenyon R. Farrow and Raphael J. Landovitz, MD, MSc, discuss key considerations to PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: Rates of HIV diagnoses in Black and Brown communitiesIssues stalling success in HIV prevention (eg, stigma, healthcare coverage, and administration and operational barriers)Considerations for healthcare professionals when discussing PrEP with patientsImportance of representation (eg, racial and ethnic minority people, transgender people) at clinic officesPromoting cultural humility to build strong patient-provider relationshipsFaculty: Kenyon R. FarrowVice President of PolicyPoint Source YouthContributing EditorTheBody.comCleveland, OhioRaphael J. Landovitz, MD, MScProfessor of MedicineDivision of Infectious DiseasesDavid Geffen School of MedicineUniversity of California, Los AngelesDirector, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment ServicesLos Angeles, CaliforniaLink to full program:https://bit.ly/3PZGYdR

In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, and Meredith Clement, MD, discuss PrEP initiation, including:The importance of taking a sexual history and getting to know your patientRecommendations for who should be considered for PrEPPracticalities of PrEP initiation including laboratory assessments, interview and physical exam, evaluating concomitant medications, counseling, and prescribingSummary of PrEP eligibility by regimenReview of the clinical trial and real-world data for each PrEP modalityThe likelihood of cross-resistance between PrEP options and ART options if someone were to become infected with HIV while receiving PrEPTime to effective concentrations of PrEP after initiationWhether there are data for on-demand dosing of FTC/TAFRecommendations for FTC/TDF on demand for heterosexual cisgender menIndividualizing PrEP for each person to increase the likelihood of adherence, persistence, and efficacyRecommendations for the use of LA CAB for PrEP during pregnancy and in people of childbearing potentialSTI and point-of-care testing for people receiving PrEPThe possibility of implantable PrEP in the futurePresenters:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDProfessor and DirectorThe Desmond Tutu HIV Centre University of Cape TownCape Town, South AfricaMeredith Clement, MD Assistant ProfessorSection of Infectious DiseasesLouisiana State University Health Sciences CenterUniversity Medical CenterNew Orleans, Louisiana Link to full program:https://bit.ly/3HPu4Lk

In this episode, Stefan Zeuzem, MD, discusses new data on viral hepatitis presented at EASL 2023, including:Hepatitis B virusDurability of response with bepirovirsenHBsAg loss with siRNA VIR-2218 combined with either VIR-3434 (novel monoclonal antibody) or pegIFN-alfaHepatitis delta virus96-week follow-up of immediate vs delayed bulevirtideOff-treatment response for lonafarnib + ritonavir ± pegIFN-alfa Safety and efficacy outcomes with siRNA JNJ-3989 + nucleos(t)ide analogueHepatitis C virusCollaborative service at opiate substitution treatment clinic to improve linkage to care in IrelandNurse-led test-and-treat program to increase screening and diagnosis at female prisons in the United KingdomFIND-C study using machine learning to improve screening-to-diagnosis ratio using clinical factors and social determinants of healthPresenter:Stefan Zeuzem, MDProfessor of Medicine Chief, Department of Medicine JW Goethe University Hospital Frankfurt, GermanyLink to full program: https://bit.ly/3JQQj3J

In this episode, Kyle Molina, PharmD, BCIDP, provides an overview of treatment of skin and soft tissue infections (SSTIs) and challenges in practice. Listen as he gives perspectives on:Guideline recommendations for treatment of purulent and nonpurulent SSTIsLogistical challenges with IV and oral antibioticsPros and cons of various locations of careData supporting the safety and efficacy of long-acting lipoglycopeptides for treatment of SSTIsUse of long-acting lipoglycopeptides in special populations of interest, including patients with obesity, diabetes, and injection drug useOverall place in therapy of long-acting lipoglycopeptides for SSTIs Faculty:Kyle Molina, PharmD, BCIDPInfectious Diseases Clinical PharmacistScripps Green HospitalLa Jolla, CaliforniaLink to full program: CCO: https://bit.ly/3J4mg8hProCE: https://bit.ly/3P0vB4E

In this episode, Latesha Elopre, MD, MSPH, and Jason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, answer questions about HIV PrEP including:How long someone can receive PrEP and the monitoring that is needed over timeRecommendations for monitoring bone health while receiving oral PrEPTreatment as prevention and PrEP efficacy data and options for people who inject drugsThe role of circumcision in HIV preventionThe use of PrEP in pregnancyConcern for ART resistance if someone seroconverts while receiving PrEP, especially when using nondaily PrEP optionsThe possibility of using FTC/TAF on demandInequities in adherence and persistenceCost considerations with different PrEP modalitiesRecommendations for hospitalized patients receiving PrEPPrEP considerations for patients with renal dysfunction and higher BMIsPrEP efficacy based on site of exposurePresenters:Latesha Elopre, MD, MSPHAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaJason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRNProfessorSchool of NursingJohns Hopkins UniversityNurse PractitionerDepartment of Infectious DiseasesJohn G. Bartlett Specialty PracticeBaltimore, MarylandLink to full program:https://bit.ly/3Fqdgs9

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP, and Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES, discuss key considerations to barriers to PrEP uptake, including:Limited data on “on-demand” PrEP in cisgender women Strategies on improving communication with non‒English-speaking populations Role of pharmacists with injectable PrEP CDC PrEP guideline recommendations on routine HIV-1 RNA testing Engaging with pregnant persons who might want access to PrEP in the pharmacy settingOral PrEP efficacy based on adherence in cisgender women, including recent data presented at CROI 2023 by Marrazzo and colleaguesPresenters: Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCPAssociate ProfessorDepartment of Pharmacy PracticeMidwestern University College of Pharmacy, Downers Grove CampusDowners Grove, IllinoisSystem-Level HIV/ID Clinical PharmacistAmbulatory PharmacyNorthwestern MedicineWheaton, IllinoisKevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCESAssistant ProfessorDepartment of Pharmacotherapy and Clinical ResearchUniversity of South FloridaClinical PharmacistTampa General Medical GroupTampa, FloridaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ZjSFhgDownloadable slides: https://bit.ly/3PsFNDt

In this episode, Robert S. Brown, Jr., MD, MPH; Nancy Reau, MD; and Eric, a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in older adults, including:Awareness of HBV and CHB in older adultsUpdated HBV screening and vaccination recommendationsMonitoring of renal and bone diseaseAdjustment of monitoring and treatment as a person with HBV agesPresenters: Robert S. Brown, Jr., MD, MPHVincent Astor Distinguished Professor of MedicineChief, Division of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkNancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisEric, person living with chronic hepatitis BLink to downloadable slides: please link to VM404 downloadable slides when readyLink to program: bit.ly/3L3Kz6l

In this episode, Tarik Asselah, MD, PhD, and Ira Jacobson, MD, provide expert insight on HDV screening, diagnosis, and management, including:Approach to screeningBarriers to screening (eg, test availability)Disease progression and complicationsDifferentiating between coinfection and superinfectionApproach to treatment (eg, whom to treat and when, treatment options, considerations for combination therapy)Management of patients with decompensated cirrhosisSurrogate markers to measure treatment successRole of correcting thrombocytopenia before initiating therapyFaculty:Tarik Asselah, MD, PhDProfessor of Medicine Department of HepatologyHôpital BeaujonUniversité de ParisClichy, FranceIra Jacobson, MDProfessor of MedicineNYU School of MedicineDirector of HepatologyDivision of Gastroenterology and HepatologyNYU Langone HealthNew York, New YorkLink to full program: https://bit.ly/3yp1Lxf 

In this episode, Helen Y. Chu, MD, MPH, shares updates on RSV vaccines, including:An overview of vaccine candidates under investigationRecently FDA-approved RSV vaccines for older adultsConsiderations for the next respiratory viral seasonCoadministration of RSV vaccines with other respiratory viral vaccines (eg, influenza, SARS-CoV-2)Target populations for RSV vaccinationRSV prevention in infants with the maternal vaccine and monoclonalFaculty:Helen Y. Chu, MD, MPHAssociate Professor of MedicineDivision of Allergy & Infectious DiseasesUniversity of Washington School of MedicineSeattle, WashingtonLink to full program: https://bit.ly/3nb25xehttps://bit.ly/3nb25xeLink to downloadable slides: https://bit.ly/3TsXym5

In this episode, Nancy Reau, MD, and Heiner Wedemeyer, MD, provide expert insight on HDV management, including:Use of noninvasive imaging or biopsy for staging liver diseaseScreening for hepatocellular carcinomaHBV treatmentRole of comedications (eg, erythropoietin, eltrombopag)Approach to complex cases, such as patients with:Significant fibrosis and low HDV RNA levelsHepatitis delta antibody positivity, but HDV RNA negativityHIV coinfectionDecompensated or recently decompensated cirrhosisFaculty:Nancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisHeiner Wedemeyer, MDProfessor and ChairmanDepartment of Gastroenterology, Hepatology and Endocrinology Hannover Medical SchoolHannover, GermanyLink to full program: http://bit.ly/3yp1Lxf

In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:Hyperlipidemia and cardiovascular disease risk among people living with HIVRecommendations for lipid screening for people living with HIVUsing HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbiditiesHow HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavirDeciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavirHow HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ARTHow HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance DatabaseMaunank Shah, MD, PhD Associate Professor Infectious Diseases Johns Hopkins University Baltimore, Maryland Link to full program: bit.ly/3pwaH2Y

In this episode, Martin Krsak, MD, MSc, FASAM, provides background and context on skin and soft tissue infections. Listen as he gives perspectives on:Epidemiology and clinical outcomesEconomic impactBacterial etiologyImportance of appropriate antimicrobial prescribingClinical presentationSeverity classification and distinction between purulent and nonpurulent infectionsRole of incision and debridement vs antimicrobial managementComplications to be ruled out prior to treatmentFaculty:Martin Krsak, MD, MSc, FASAMAssociate Professor of MedicineDivision of Infectious Diseases University of Colorado School of MedicineDenver, ColoradoLink to full program: CCO: https://bit.ly/3J4mg8hProCE: https://bit.ly/3P0vB4E

In this episode, Marta Boffito, MD, PhD, FRCP, and Michelle Cespedes, MD, MS, discuss initial ART options, including:Recommended first-line ART options for most PWH according to DHHS, IAS-USA, EACS, BHIVA, and WHO guidelines Data for weight gain after ART initiation with different ARV classes and drugsWeight gain disparities by race and gender after ART initiationData from the RESPOND study including risk factors for weight gain and CV event risk with INSTI vs non-INSTI–based ART The impact of INSTIs on CV events in the Swiss HIV Cohort study Recommendations for ART and contraception for PWH of childbearing potential Drug–drug interactions between first-line ART and contraceptive options Guideline-recommended first-line ART options in pregnancy with a discussion of how these regimens differ from those recommended for most PWH Marta Boffito, MD, PhD, FRCP Consultant Physician Clinical Director, HIV, Sexual and Gender Health, Dermatology Chelsea and Westminster Hospital NHS Foundation Trust Imperial College London London, United Kingdom Michelle Cespedes, MD, MS Professor of Medicine Division of Infectious Disease Department of Medicine Icahn School of Medicine at Mount Sinai New York, New York Link to full program: bit.ly/3HPu4Lk

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for PWH coinfected with HBV and HCV. Listen as she covers:How HIV-ASSIST supports ART selection in primary careUpdates to viral hepatitis recommendations including:               CDC HBV screening and testing recommendations             AASLD simplified HCV treatment approach for PWHHIV-ASSIST for managing HIV/HBV coinfections, including ensuring that NRTIs that are effective for both HIV and HBV are included in an ART regimen and alerting the user when an additional HBV treatment is needed HIV-ASSIST for managing HIV/HCV coinfections, including showing how the HIV-ASSIST tool incorporates drug‒drug interaction considerations from the University of Liverpool HIV Drug Interaction CheckerCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Clinical OfficerNational Clinician Consultation CenterProfessorClinical Family Community MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaLink to full program: bit.ly/3pwaH2Y    

In this episode, Amanda Binkley, PharmD, BCIDP, AAHIVP, and Nimish Patel, PharmD, PhD, AAHIVP, discuss clinically relevant data on long-acting ART from CROI 2023, including:LA CAB + RPV in San Francisco’s Ward 86 Safety Net Clinic Serving Publicly Insured PWHSOLAR: Randomized Switch to LA CAB + RPV From BIC/FTC/TAFAmanda Binkley, PharmD, BCIDP, AAHIVPClinical Pharmacy Specialist Infectious DiseaseDepartment of PharmacyPenn Presbyterian Medical CenterPhiladelphia, PennsylvaniaNimish Patel, PharmD, PhD, AAHIVPProfessorDepartment of Clinical PharmacySkaggs School of Pharmacy & Pharmaceutical SciencesUniversity of CaliforniaLa Jolla, CaliforniaLink to full program: bit.ly/3ZjSFhg

In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimensMaintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABCART regimen simplificationWhen to perform genotypic resistance testing, including for PWH who have been off ARTWhen to perform DNA genotyping for archived resistance testingConsidering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ARTUsing boosted DRV + DTG in salvage regimensSwitching from boosted PIs to INSTIs in PWH receiving second-line therapySecond-line regimens with LA CAB + RPV failure Christine Katlama, MD Professor Sorbonne University APHP Paris Head, HIV/Hepatitis Clinical and Research Unit Department of Infectious Diseases Paris, France Babafemi Taiwo, MBBS Gene Stollerman Professor of Medicine Chief, Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago, Illinois Link to full program: https://bit.ly/3Z44Gq3

In this episode, Sonya Krishnan, MD, MHS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for a virologically suppressed PWH who is planning a pregnancy. Listen as she covers:How to input patient specific factors into the HIV-ASSIST toolDiscussion of available education sheets to review the data and recommendations for her current ART regimen in pregnancyAn explanation of why some regimens are ranked lower because of adherence factors such as increased pill burden or dosing frequencyGuidelines informing the HIV-ASSIST output, including DHHS and IAS-USA, and the frequency with which updates are incorporatedHow to use the HIV-ASSIST output to guide regimen selection in pregnancyUse of the HIV-ASSIST tool in shared decision-making and patient counselingSonya Krishnan, MD, MHSAssistant ProfessorDivision of Infectious DiseasesJohns Hopkins UniversityBaltimore, MarylandLink to full program: bit.ly/3pwaH2Y

In this episode, Ian Frank, MD, discusses long-acting HIV treatment with cabotegravir plus rilpivirine for people with HIV, including:Efficacy data with every-8-week dosingReal-world use in people with viremia Initiation and continuation strategiesVirologic failure dataSafety information Presenter:Ian Frank, MDAssociate ChiefDivision of Infectious DiseasesProfessor of MedicineUniversity of PennsylvaniaPhiladelphia, PennsylvaniaTo download the slides: https://bit.ly/3HX1GGn To view the full online program: https://bit.ly/3ZjSFhg 

In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:Treatment in special populationsREDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumoniaRemdesivir and readmission for COVID-19 in immunocompromised patientsMolnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancyManagement of patients with severe diseaseRECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19Real-world study of tocilizumab vs baricitinib for severe COVID-19Novel antiviralsEnsitrelvirBemnifosbuvir Novel vaccinesNB2155AZD2816/AZD1222qNIV/CoV2373GRT-R910NVX-CoV2373 in people with HIVFaculty:  Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPIProfessor of Microbial DiseasesCentre for Experimental Pathogen Host ResearchUniversity College DublinDublin, IrelandContent based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.  Link to full program: bit.ly/3niXGJ6Link to downloadable slides: bit.ly/3LUFejG

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO

In this episode, David van Duin, MD, PhD, FIDSA, FAST, discusses new data on complicated clinical infections presented at ECCMID 2023, including:Gram-negative resistancePharmacokinetic and clinical outcomes in patients receiving meropenem/vaborbactam for KPC-producing carbapenem-resistant Enterobacterales infectionsComparative study of cefiderocol- vs colistin-containing regimens for CRAB VAP with concomitant bacteremiaReal-world use of imipenem/cilastatin/relebactam for the treatment of infections caused by multidrug-resistant organismsAntimicrobial stewardshipSafety and efficacy of antibiotic de-escalation from an antipseudomonal β-lactam in patients with Enterobacterales BSIs in SIMPLIFYThe SOAB study comparing clinical outcomes of switching to oral antibiotics after IV lead-in therapy vs continuing IV therapy in patients with Enterobacterales BSIsData from REGARD-VAP on outcomes of shortened antibiotic treatment for VAP guided by clinical criteriaInvestigational agentsOpen-label study following ATTACK of patients with colistin-resistant CRAB infections receiving sulbactam/durlobactamSummary of findings from EAGLE-2 and EAGLE-3 of gepotidacin for uncomplicated UTI treatmentPost hoc DOOR analysis of SURE-2 of sulopenem for the treatment of complicated UTIs Faculty: David van Duin, MD, PhD, FIDSA, FAST Professor of Medicine Director, Immunocompromised Host Infecious Diseases Program Division of Infectious Diseases University of North Carolina Chapel Hill, North Carolina Content based on an online CME/CE program supported by an independent educational grant from Shionogi Inc. Link to full program: https://bit.ly/3niXGJ6Link to downloadable slides: https://bit.ly/3Hx0ppn

In this episode, Tracey Piparo, PA-C, and Renslow Sherer, MD, discuss cases of nonhospitalized patients with COVID-19, including:Young, healthy patient with no risk factorsYoung, healthy patient with risk factorsOlder patient with immunocompromiseOlder patient with renal dysfunctionPatient experiencing hypoxia Presenters: Tracey Piparo, PA-C Department of Palliative Medicine RJWBarnabas New Brunswick, New Jersey Renslow Sherer, MD Director, International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois To download the slides: bit.ly/44cgH0qTo view the full online program: https://bit.ly/4201xcO

In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:Barriers to HDV screening, including limitations to AASLD guideline recommendationsUse of double reflex testing to improve HDV diagnosisConsiderations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDVUpdated CDC recommendations for HBV screening for all adults using a triple panel test Staging advanced liver disease in patients with HDVIndications for HDV treatment, including patients with low ALT levels and advanced or progressive liver diseaseTreatment landscape for HDVPersonal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosisUpdates on novel HDV therapies, including:Summary of efficacy data on bulevirtide from clinical trialsInterpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib Link to full program: bit.ly/3yp1Lxf

In this episode, Joseph Lim, MD; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and Jennifer Wild, MS, BSN, RN, OCN, discuss strategies for overcoming barriers to HBV care in Asian American people, including:HBV-related stigmaLanguage barriersHealth insurance navigationPresenters:Joseph Lim, MDProfessor of Medicine Director, Clinical HepatologyVice-Chief, Section of Digestive DiseasesYale University School of MedicineNew Haven, Connecticut Mindie H. Nguyen, MD, MAS, AGAF, FAASLDProfessor of Medicine (GI & Hepatology, Liver Transplant) Professor of Epidemiology & Population Health (By Courtesy)Director of Hepatology Fellowship Director of Hepatology ClerkshipStanford University Medical CenterPalo Alto, CaliforniaJennifer Wild, MS, BSN, RN, OCN Clinical NurseUCSF Helen Diller Family Comprehensive Cancer CenterGI Medical Oncology, Outpatient Hepatobiliary ProgramOakland, CaliforniaLink to downloadable slides: please link to VM401 downloadable slides when readyLink to program: please link to HEP 2023 HBV Key Communities VM (PRP5676) when ready

In this episode, Essa Mohamed, PhD; Daouda Ndiaye; and Ponni Perumalswami, MD, MS, discuss strategies for overcoming barriers to HBV care in African immigrant people, including:HBV awareness and misconceptionsHBV-related stigmaLanguage barriersHealth insurance navigationPresenters:  Essa Mohamed, PhDClinical ResearcherDivision of Gastroenterology and HepatologyMayo ClinicRochester, MinnesotaDaouda NdiayePatient NavigatorPonni Perumalswami, MD, MSAssociate Professor of Internal MedicineDivision of Gastroenterology and HepatologyUniversity of MichiganAnn Arbor, MichiganLink to program: bit.ly/3L3Kz6l 

In this episode, Daniel R. Kuritzkes, MD, discusses considerations for patients experiencing weight gain on antiretroviral therapy, including:• Commonly implicated antiretroviral therapy regimens and patient populations• Guideline recommendations for management of weight gainPresenter:Daniel R. Kuritzkes, MDHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolChief, Division of Infectious DiseasesBrigham and Women’s HospitalBoston, MassachusettsTo download the slides: bit.ly/3odUA9CTo view the full online program: bit.ly/3ZjSFhg

In this episode, Isolde Butler, MD, and Brenda E. Crabtree Ramírez, MD, discuss rapid ART initiation for people newly diagnosed with HIV, including:The HIV care continuum in the United States and Latin AmericaBarriers to HIV diagnosis, including stigma, discriminatory laws and policies, social determinants of health, and lack of access to healthcareFactors that predict delayed care linkage and inconsistent HIV care and treatmentImproved clinical outcomes that have been shown with rapid ART initiation, first in low- and middle-income countries and now worldwideRecommendations for rapid ART—and regimen choices—from the DHHS, IAS-USA, CENSIDA, EACS, and WHORecommendations for transitioning from PrEP to ART when someone seroconverts while receiving either oral PrEP or LA CAB for PrEPBarriers to rapid ART initiation in their individual care settingsThe future of LA injectable ART for initial treatment and rapid initiationIsolde Butler, MDChief Medical OfficerCrescentCareNew Orleans, LouisianaBrenda E. Crabtree Ramírez, MDAssistant Professor, HIV ProgramDepartment of Infectious DiseasesInstituto Nacional de Ciencias Médicas y Nutrición, Salvador ZubiránMexico City, MexicoLink to full program: bit.ly/3HPu4Lk

In this episode, Daniel R. Kuritzkes, MD, discusses considerations for rapid initiation of antiretroviral therapy in patients who are newly diagnosed with HIV, including:Recommended regimensManagement of patients previously receiving PrEPTiming of laboratory testingPresenter:Daniel R. Kuritzkes, MDHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolChief, Division of Infectious DiseasesBrigham and Women’s HospitalBoston, MassachusettsTo download the slides: https://bit.ly/3odUA9CTo view the full online program: https://bit.ly/3ZjSFhg

In this episode, 2 HIV experts from the Asia-Pacific region share their thoughts on some of the most important new insights from HIV treatment and prevention research over the past year.Specifically, the faculty discuss the role of newer innovations in HIV, including 2-drug oral antiretroviral therapy (ART) regimens, 2-drug long-acting injectable ART, and long-acting HIV pre-exposure prophylaxis in HIV care in the Asia-Pacific region, as well as the implications of weight gain with ART and important considerations related to the unique challenges associated with caring for the aging population of people with HIV in the region.Presenters:Anchalee Avihingsanon, MD, PhDHIV-NAT, Thai Red Cross AIDS Research CentrePathumwan, Bangkok, Thailand Senior Clinical TrialMedicineBangkok, ThailandReena Rajasuriar, BPharm, MPharm, PhDAssociate ProfessorDepartment of MedicineUniversity of MalayaKuala Lumpur, MalaysiaContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare. Link to full program: bit.ly/3Hz0jNa 

In this episode, Angela Branche, MD, and Helen Y. Chu, MD, MPH, discuss the clinical presentation of respiratory syncytial virus (RSV) in adults and the importance of early detection, including:  Clinical symptoms and presentation  Complications, including exacerbations of cardiopulmonary diseasesUse of medical resources compared with other respiratory virusesDiagnostic approaches and challengesTreatment and management of RSV diseaseClinical impact of RSV awarenessFaculty:  Angela Branche, MDAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkHelen Y. Chu, MD, MPHAssociate Professor of MedicineDivision of Allergy & Infectious DiseasesUniversity of Washington  School of MedicineSeattle, WashingtonLink to full program: bit.ly/3nb25xeLink to downloadable slides:bit.ly/3TsXym5

In this episode, Angela Branche, MD, and Helen Y. Chu, MD, MPH, discuss the impact of respiratory syncytial virus (RSV) and describe those at risk for severe RSV disease, including: RSV prevalence and seasonality  RSV burden throughout life, including burden in older adultsComorbidities that increase the risk of RSV complications  RSV transmission in the hospital and care home settingImplications of risk factors for severe RSV on prevention and treatment    Faculty: Angela Branche, MDAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkHelen Y. Chu, MD, MPHAssociate Professor of MedicineDivision of Allergy & Infectious DiseasesUniversity of Washington  School of MedicineSeattle, WashingtonLink to full program: bit.ly/3nb25xeLink to downloadable slides: bit.ly/3TsXym5

In this episode, José R. Arribas, MD, and Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP, discuss optimizing antiretroviral therapy (ART) for people with HIV who are treatment experienced or failing a current ART regimen, including:The use of proviral DNA genotyping for switching therapyMaintaining nucleos(t)ide reverse-transcriptase inhibitors after a first failureThe role of zidovudine in salvage regimensThe use of twice-daily darunavir with protease inhibitor resistance and twice-daily dolutegravir with integrase strand transfer inhibitor resistanceSimplification of regimens and long-acting therapies for people with HIV who are highly treatment experiencedDrug‒drug interactions that may warrant dosing changes to avoid resistance developmentWhen to consider antiretrovirals with novel mechanisms of action, such as fostemsavir, ibalizumab, and lenacapavirThe logistics of dosing, administration, and development of a complete ART regimen that includes novel mechanism antiretroviralsAddressing psychosocial factors to increase the chance of success on a new ART regimenDrug‒drug interactions with novel mechanism agentsHow common ART resistance is for people with HIV in their own practicesThe possibility of using long-acting cabotegravir plus rilpivirine in people with viremia in the futureAddressing low-level viremiaJosé R. Arribas, MDProfessor of MedicineDepartment of MedicineAutónoma University School of MedicineHead, Infectious Diseases UnitDepartment of Internal MedicineHospital La PazMadrid, SpainMelissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVPClinical Associate ProfessorSection of Infectious Diseases Pharmacotherapy Department of Pharmacy PracticeUniversity of Illinois at Chicago, College of PharmacyChicago, IllinoisLink to full program:bit.ly/3Z44Gq3

In this episode, Darrell H. S. Tan, MD, FRCPC, PhD, and Kenric Ware, PharmD, AAHIVP, discuss considerations for HIV pre-exposure prophylaxis (PrEP) persistence, including:The PrEP continuum of care in the United States, including inequities in PrEP uptake and persistence by raceCDC PrEP guidance regarding PrEP indicationsPrEP eligibility by regimenSummary of renal, bone, and weight outcomes with different PrEP optionsData on HIV acquisition following PrEP discontinuationDrug concentrations and recommendations for stopping long-acting cabotegravir for PrEPExpanding PrEP options to facilitate adherence and persistenceProviding PrEP by telehealthPresenters:Darrell H. S. Tan, MD, FRCPC, PhDAssociate ProfessorDivision of Infectious DiseasesUniversity of TorontoClinician-ScientistDivision of Infectious DiseasesSt. Michael’s HospitalToronto, CanadaKenric Ware, PharmD, AAHIVPAssociate ProfessorDepartment of Pharmacy PracticeSouth UniversitySavannah, GeorgiaChairperson, PharmacistBoard of DirectorsJoseph H. Neal Health CollaborativeColumbia, South CarolinaLink to full program:https://bit.ly/3HPu4Lk

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, and Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, answer questions including:Strategies to improve disparities in pre-exposure prophylaxis (PrEP) access in difficult-to-reach populations Key remaining questions related to PrEP options for cisgender women and people who inject drugsConcerns about resistance at seroconversion in patients with suboptimal PrEP complianceImplementation of molecular screening for patients receiving PrEPExpectations for weight gain and patient counseling pointsPresenters:Carolyn Chu, MD, MSc, FAAFP, AAHIVSChief Medical OfficerAmerican Academy of HIV MedicineChief Clinical OfficerNational Clinician Consultation CenterSamantha Strong, PharmD, BCACP, AAHIVP, CDCES Clinical Director of PharmacyNevada Health CentersLas Vegas, NevadaLink to full program: https://bit.ly/3Fqdgs9